{
  "meta": {
    "title": "Androgen insensitivity syndrome",
    "url": "https://brainandscalpel.vercel.app/androgen-insensitivity-syndrome-65966fa4-cf563c.html",
    "scrapedAt": "2025-12-01T04:53:02.380Z",
    "type": "article"
  },
  "content": "\n                <div><h1>Introduction</h1>\n<p>Androgen insensitivity syndrome (AIS) is a rare, X-linked recessive disorder of sex development caused by defective androgen receptors.&nbsp; Patients with complete AIS have a 46,XY genotype yet have a female phenotype (ie, female external genitalia, breast development) despite the presence of testes and male-range androgen production (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L19580.jpg\" alt=\"figure 1\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 1</div>\n                                </div>\n                                ).<p></p>\n<h1>Pathogenesis</h1><br><br><p>Testosterone and dihydrotestosterone (DHT) normally interact with androgen receptors in target tissues to induce androgenic effects (ie, virilization).</p><br><br><p>AIS, an X-linked recessive disorder, is caused by loss-of-function mutations in the androgen receptor gene on the X chromosome.&nbsp; These mutations lead to a lack of response to androgens, resulting in abnormal sexual development (ie, undervirilization) beginning in utero:</p>\n<h2>Development of internal genitalia</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li><strong>46,XY</strong> patients with AIS have an intact <em>SRY</em> gene&nbsp;on the Y chromosome, which induces the embryonic gonadal ridges to differentiate into <strong>testes</strong> (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L29882.png\" alt=\"figure 2\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 2</div>\n                                </div>\n                                ).&nbsp; In the testes, Sertoli cells produce anti-mÃ¼llerian hormone (AMH) and Leydig cells produce testosterone.</li>\n\t<li>AMH causes regression of the mÃ¼llerian structures; therefore, patients with AIS do not develop female internal genitalia (eg, uterus, cervix, upper third of the vagina).</li>\n\t<li>However, because testosterone cannot bind to the nonfunctioning androgen receptors within wolffian ducts, internal male genitalia (eg, vas deferens, seminal vesicles, epididymis) are absent.</li>\n</ul>\n<h2>Development of external genitalia</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Testosterone is converted into DHT by the enzyme 5-alpha reductase.&nbsp; Normally, DHT stimulates testicular descent and induces embryonic structures (eg, genital tubercle (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L1434.jpg\" alt=\"figure 3\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 3</div>\n                                </div>\n                                )) to differentiate into male external genitalia (eg, penis).</li>\n\t<li>Patients with AIS have no response to DHT because of their defective androgen receptors.&nbsp; As a result, male external genitalia do not develop and the testes remain undescended (<strong>cryptorchid</strong>).&nbsp; In the absence of DHT activity, <strong>female external genitalia</strong> (eg, lower two-thirds of the vagina, vulva) develop.</li>\n</ul><br><br><p>Testosterone is not overtly elevated because it is peripherally aromatized to estrogen.&nbsp;</p><br><br><p>At puberty, the testes increase production of testosterone to male-range levels, causing increased estrogen production through aromatization.&nbsp; Therefore, patients with AIS undergo <strong>breast development</strong> because of the combination of androgen resistance (testosterone suppresses breast development) and high levels of estrogen.&nbsp; Peripheral androgen resistance also results in <strong>minimal or absent axillary and pubic hair</strong>.&nbsp; Menses are absent due to the absence of female internal genitalia (ie, uterus).&nbsp; The testes remain cryptorchid with impaired spermatogenesis.</p>\n<h1>Clinical presentation</h1><br><br><p>Classically, complete AIS presents during adolescence with a female phenotype and the following features:</p><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Primary amenorrhea (ie, absence of menarche by age 15 in girls with secondary sexual characteristics [eg, breast development])</li>\n</ul><br><br><p>Examination typically shows:</p><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Minimal or absent axillary and pubic hair</li>\n\t<li>Normal breast development (eg, sexual maturity [Tanner] stage 4)</li>\n\t<li>Normal female external genitalia (eg, vulva)</li>\n\t<li>A short, blind vaginal pouch</li>\n\t<li>Usually, intraabdominal testes that are occasionally palpable in the inguinal canal or labia majora</li>\n\t<li>Tall stature</li>\n</ul><br><br><p>However, depending on the degree of impaired androgen receptor function, AIS can produce a range of phenotypes of varying levels of undervirilization.&nbsp; These range from classic complete AIS, partial AIS (mostly female phenotype with mild pubertal virilization [eg, clitoromegaly]), and mild AIS (eg, predominantly male phenotype but impaired spermatogenesis and gynecomastia).</p>\n<h1>Diagnosis</h1><br><br><p>The diagnosis may be delayed until <strong>after puberty</strong> (when a patient is evaluated for primary amenorrhea) because patients with complete AIS have female external genitalia at birth and normal breast development at puberty.</p><br><br><p>Primary amenorrhea evaluation includes history (particularly pubertal development), physical examination, hormonal evaluation, and imaging (internal reproductive organ assessment).&nbsp; AIS is suspected with the following features:</p><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Female phenotype (ie, female external genitalia)</li>\n\t<li>Abnormal female pubertal development:\n\t<ul class=\"article-body-unordered-list\">\n\t\t<li>Adrenarche:&nbsp; minimal or absent axillary and pubic hair</li>\n\t\t<li>Thelarche:&nbsp; normal breast development</li>\n\t\t<li>Menarche:&nbsp; absent menses</li>\n\t</ul>\n\t</li>\n\t<li>A blind vaginal pouch</li>\n\t<li>Absent uterus on pelvic ultrasonography</li>\n\t<li>Elevated (ie, male-range) testosterone levels</li>\n</ul><br><br><p><strong>Karyotyping</strong> (ie, 46,XY) and/or <strong>sequencing</strong> of the androgen receptor gene confirms the diagnosis.</p>\n<h1>Differential diagnosis</h1><br><br><p>The differential diagnosis for AIS includes other differences of sex development that present with a female phenotype, primary amenorrhea, and abnormal pubertal development (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/73707.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">ðŸ“Š</span> View Table: table 1\n                                    </a>\n                                </div>\n                                ); these features usually indicate a genetic or anatomic abnormality:<p></p><br><br><ul class=\"article-body-unordered-list\">\n\t<li><strong>MÃ¼llerian agenesis</strong> (ie, Mayer-Rokitansky-KÃ¼ster-Hauser syndrome or congenital absence of the vagina [46,XX]):&nbsp; presents with female external genitalia, primary amenorrhea, a blind vaginal pouch, and absent or rudimentary uterus.&nbsp; The ovaries are normal and functioning, therefore, patients have breast development.&nbsp; However, testosterone levels are in the normal female range, and axillary/pubic hair is present.</li>\n\t<li><strong>Female gonadal dysgenesis</strong> (eg, Turner syndrome [45,X]):&nbsp; presents with female external genitalia and primary amenorrhea; however, patients have female internal genitalia (uterus, fallopian tubes), streak ovaries, minimal breast development (due to deficient estrogen production), and normal axillary/pubic hair.</li>\n\t<li><strong>5-Alpha-reductase deficiency</strong> (46,XY):&nbsp; presents with ambiguous (undervirilized) or female external genitalia at birth because DHT (the hormone required for differentiation of male external genitalia) is absent during embryogenesis; however, male internal genitalia are present due to testosterone-induced wolffian duct development.&nbsp; At puberty, testosterone reaches male-range levels, causing marked virilization (eg, clitoromegaly).&nbsp; Patients do not develop breasts because androgen receptors are functional, which allows testosterone to inhibit breast development and prevents peripheral aromatization into estrogen.&nbsp; Axillary and pubic hair are present due to functioning androgen receptors.</li>\n\t<li><strong>Complete male gonadal dysgenesis</strong> (ie, Swyer syndrome [46,XY]):&nbsp; presents with female external genitalia and primary amenorrhea.&nbsp; However, the mÃ¼llerian structures (eg, uterus, fallopian tubes, vagina) are intact due to abnormal testes development and the subsequent lack of AMH and testosterone during embryogenesis.&nbsp; Testosterone is low and axillary and pubic hairs are minimal.</li>\n</ul>\n<h1>Management</h1><br><br><p>Management options are individualized for each patient and typically include:</p><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Psychosocial support for the patient and family</li>\n\t<li>Maintenance of sexual function\n\t<ul class=\"article-body-unordered-list\">\n\t\t<li>Estrogen replacement therapy to induce and maintain female secondary sexual characteristics</li>\n\t\t<li>Dilator therapy of the vagina or vaginal surgery to improve sexual function in adulthood</li>\n\t</ul>\n\t</li>\n\t<li>Management of cryptorchid testes\n\t<ul class=\"article-body-unordered-list\">\n\t\t<li>MRI may be required to locate the testes.</li>\n\t\t<li>Prophylactic gonadectomy may be considered after puberty to reduce the risk for testicular cancer associated with AIS (eg, cryptorchid testes).</li>\n\t</ul>\n\t</li>\n</ul>\n<h1>Prognosis</h1><br><br><p>The long-term prognosis for complete AIS is typically good, although fertility options are limited due to impaired spermatogenesis.</p>\n<h1>Summary</h1><br><br><p>Androgen insensitivity syndrome (AIS) (46,XY) (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/42379.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">ðŸ“Š</span> View Table: table 2\n                                    </a>\n                                </div>\n                                ) is a rare, X-linked recessive disorder of sexual development caused by androgen receptor dysfunction.&nbsp; Complete AIS presents with female external genitalia and normal breast development.&nbsp; The diagnosis is often made when patients experience primary amenorrhea following puberty.&nbsp; Evaluation typically shows minimal axillary and pubic hair, a blind vaginal pouch, absence of the uterus, elevated (ie, male-range) testosterone levels, and cryptorchid testes.&nbsp; Genetic testing confirms the diagnosis.<p></p>\n</div>\n\n            "
}